2673-Industry news-CACLP-The largest IVD Expo & Conference

1 results for “Oncomine” in Newsroom

Sort by date

Industry news | 28 September, 2022
Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers

Thermo Fisher Scientific said on Tuesday that its next-generation sequencing-based Oncomine Dx Target Test has been approved by the US FDA as a companion diagnostic (CDx) to identify patients with advanced RET-driven lung and thyroid cancers who may be eligible for Lilly’s Retevmo (selpercatinib).

Content types Reset

✔ All (1)

✔ Press release (0)

✔ Industry news (1)

Opening Countdown

0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Visitor registration Book your stand

CACLP - The largest IVD Expo & Conference

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Visit Exhibit Conferences Webinars Newsroom About Us FAQs

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

No, thanks. Yes, I agree.

Subscribe to CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.

Name *
Email *
Telephone
Job title
Company name *
Country *

By submitting the form here, you agree to our Privacy Policy and agree that we may store and access the information you provide.

Thank you for subscribing to CACLP News!

To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.

Go back

1 results for “Oncomine” in Newsroom

Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers

Stay in touch with CACLP News

Subscribe to CACLP News

Thank you for subscribing to CACLP News!